Sei Investments Co. increased its position in shares of Novartis AG (NYSE:NVS) by 5.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,273,150 shares of the company’s stock after buying an additional 63,402 shares during the quarter. Sei Investments Co. owned 0.06% of Novartis worth $120,624,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Timber Creek Capital Management LLC lifted its position in shares of Novartis by 0.3% in the fourth quarter. Timber Creek Capital Management LLC now owns 37,818 shares of the company’s stock valued at $3,581,000 after buying an additional 105 shares during the last quarter. First Hawaiian Bank lifted its position in shares of Novartis by 1.6% in the fourth quarter. First Hawaiian Bank now owns 7,109 shares of the company’s stock valued at $674,000 after buying an additional 113 shares during the last quarter. Baystate Wealth Management LLC lifted its position in shares of Novartis by 22.5% in the third quarter. Baystate Wealth Management LLC now owns 625 shares of the company’s stock valued at $54,000 after buying an additional 115 shares during the last quarter. Watch Point Trust Co lifted its position in shares of Novartis by 0.3% in the fourth quarter. Watch Point Trust Co now owns 42,657 shares of the company’s stock valued at $4,039,000 after buying an additional 115 shares during the last quarter. Finally, Leavell Investment Management Inc. lifted its position in shares of Novartis by 3.9% in the third quarter. Leavell Investment Management Inc. now owns 3,134 shares of the company’s stock valued at $272,000 after buying an additional 119 shares during the last quarter. Institutional investors and hedge funds own 10.61% of the company’s stock.

A number of analysts have recently issued reports on the company. Cowen reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Novartis in a research report on Friday, October 25th. ValuEngine raised Novartis from a “sell” rating to a “hold” rating in a research report on Saturday, October 19th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. Novartis currently has a consensus rating of “Hold” and an average target price of $93.34.

Shares of NVS traded down $0.14 during mid-day trading on Friday, reaching $97.63. The company’s stock had a trading volume of 1,058,244 shares, compared to its average volume of 1,886,027. Novartis AG has a 1-year low of $74.97 and a 1-year high of $99.84. The stock has a market cap of $223.77 billion, a P/E ratio of 19.33, a PEG ratio of 2.14 and a beta of 0.64. The business has a 50-day simple moving average of $95.15 and a two-hundred day simple moving average of $90.83. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.40.

The company also recently declared an annual dividend, which will be paid on Thursday, March 12th. Investors of record on Wednesday, March 4th will be issued a dividend of $3.0425 per share. This is a boost from Novartis’s previous annual dividend of $2.86. This represents a yield of 2%. The ex-dividend date of this dividend is Tuesday, March 3rd. Novartis’s dividend payout ratio (DPR) is presently 35.11%.

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Recommended Story: What is a balanced fund?

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.